Stayble Therapeutics publishes half-year report for 2022
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the half-year report for 2022. The report is available as an attached document and on the Company's website.
Highlights during the second quarter (April – June 2022)
- Stayble announces that it has enrolled 75% of all patients in the ongoing Phase IIb clinical trial. Multiple efforts to increase patient enrollment coupled with the reduced impact of the Covid-19 pandemic have resulted in a significant increase in recruitment rates. The recruitment rate is in line with the set timeline and the final target to enroll all patients during the year.
- Stayble announces that the Company will change its liquidity guarantor to Lago Kapital AB, starting May 9, 2022. Stayble has terminated its current liquidity guarantee agreement with Mangold Fondkommission AB.
Highlights after the end of the period
- No highlights after the end of the period.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail ca@skmg.se